External R&D Is Up, But Which Companies Are Reaping The Most Benefit?
Executive Summary
Amgen, Novartis and Lilly are projected to increase sales from externally sourced assets in the coming years, according to a Datamonitor Healthcare analysis, while other big pharma – including frequent acquirer Pfizer and smaller-deal-oriented Bristol – are expected to see that ratio decline compared to sales of internally developed drugs.
You may also be interested in...
Biopharma R&D Productivity And Growth 2016: Innovation Performance Improves
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
In-Licensed Drugs Bring More Growth Than In-House, Study Shows
Datamonitor Healthcare analysis finds that as companies across the biopharmaceutical industry rely increasingly on externally sourced assets, per-drug revenue bears out this strategy. Part one of a series on the review of the impact, and potential, of externalizing R&D.
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.